Context Therapeutics Inc. · NASDAQ:CNTX
Context Therapeutics — Investor Presentation (March 2023)
30 slides from Context Therapeutics's investor presentation, Mar 22, 2023
Slide 1: Advancing Medicines for Solid Tumors
March 2023 Corporate Presentation Advancing Medicines for Solid Tumors
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances
Slide 3: Context Therapeutics Overview
Context Therapeutics Overview Context Therapeutics Inc. - March 20233 Company Overview CTIM-76 CLDN6 x CD3 bispecific antibody • CTIM-76 is Context’s CLDN6 x CD3 bispecific antibody Development Candidate • Claudin 6 (CLDN6) is uniquely expressed in a broad range of solid tumors, including ovarian, l
Slide 4: Emerging Role of Bispecific Antibodies in Treating Solid Tumors
Emerging Role of Bispecific Antibodies in Treating Solid Tumors Harnessing the Immune System to Attack Solid Tumors • A challenge for targeting solid tumors is that many tumor-associated antigens are also expressed on normal tissues, raising concerns about “on-target off-tumor” toxicities • Bispecif
Slide 5: Claudin (CLDN6) is an Ideal Target for Bispecific Antibodies
Claudin 6 (CLDN6) is an Ideal Target for Bispecific Antibodies Opportunity • CLDN6 is a tumor-specific protein that is present at high surface density across many adult and pediatric cancers1 • CLDN6 is expressed at very low levels or absent in normal adult tissue Challenge • CLDN6 antigen is confor
Slide 6: CLDN6 Has the Potential to Reach a Large Patient Population
CLDN6 Has the Potential to Reach a Large Patient Population ~62,500 patients per year in the US only in Relapse/Refractory Setting Company Overview 6 Selected Cancer indications Incidence R/R Incidence CLDN6 Positive Patient Population Based on R/R Incidence Testicular 9,910 400 95%1 380 Ovarian 19,
Slide 7: Claudin (CLDN6) Target biology and therapeutic rationale
Claudin 6 (CLDN6) Target biology and therapeutic rationale Context Therapeutics Inc. - March 20237
Slide 8: Claudin (CLDN) Protein Family
Claudin (CLDN) Protein Family • Tight junctions (TJ) regulate cell barrier and permeability • CLDN proteins constitute a structural core of TJ, along with junction adhesion molecule (JAM) and occludin • 27 CLDN proteins have been characterized to date • Dysregulation of CLDN protein expression and f
Slide 9: The Challenge: developing a highly selective CLDN6 antibody
The Challenge: developing a highly selective CLDN6 antibody CLDN6 Target Biology Context Therapeutics Inc. - March 20239 CLDN9 CLDN6 CLDN4 CLDN3 CLDN5 CLDN8 CLDN17 CLDN2 CLDN14 CLDN20 CLDN7 CLDN1 CLDN19 CLDN34 CLDN12 CLDN23 CLDN16 CLDN24 CLDN22 CLDN25 CLDN18 CLDN11 CLDN15 CLDN10 • CLDN6 antigen is c
Slide 10: CLDN6 is an Oncofetal Protein
CLDN6 is an Oncofetal Protein Oncofetal proteins are considered favorable candidates for immunotherapy • Normally present at higher levels during embryonic development • Turned off or have low levels of expression in adult tissues • Increased expression of these antigens can occur in some tumor cell
Slide 11: CLDN6 is Selectively Expressed on Cancer Cells
CLDN6 is Selectively Expressed on Cancer Cells CLDN6 Target Biology Context Therapeutics Inc. - March 202311 (a) adrenal gland, (b) fallopian tube, (c) kidney, (d) liver, (e) thyroid, (f) prostate, (g) esophagus, (h) stomach, (i) colon, (j) cerebrum, (k) cerebellum, (l) spinal cord. (m) thymus, (n)
Slide 12: High CLDN6 Associated with a Worsened Prognosis in Cancer Patients
High CLDN6 Associated with a Worsened Prognosis in Cancer Patients CLDN6 Target Biology Context Therapeutics Inc. - March 202312 Endometrial Cancer1 Overexpression of CLDN6 is associated with worse overall survival in endometrial cancer patients 1 Kojima, Cancers, 2020 2 Zhang, Front. Cell Dev. Biol
Slide 13: CTIM-76 Claudin x CD3 Development Candidate
CTIM-76 Claudin 6 x CD3 Development Candidate Context Therapeutics Inc. - March 202313
Slide 14: Bispecific Antibody Considerations
• Multiple formats evaluated Bispecific Antibody Considerations Bispecific scaffold and CLDN6/CD3 arms evaluated to optimize selectivity, potency, and manufacturability Discovery of CTIM-76 Context Therapeutics Inc. - March 202314 NHP = non-human primate FcR = fragment crystallizable region (Fc regi
Slide 15: CTIM-76: Claudin x CD3 Bispecific Antibody
CTIM-76: Claudin 6 x CD3 Bispecific Antibody Wide therapeutic window • Highly selective CLDN6 binding fragment antibody-binding (Fab) arm • Immunostimulatory CD3 binding single-chain fragment variable (scFv) domain is designed to be functionally monovalent to avoid aberrant T-cell activation, potent
Slide 16: Role of Bispecific Format in Activity
Role of Bispecific Format in Activity CTIM-76 format demonstrates superior potency compared to a traditional BiTE molecule Discovery of CTIM-76 Context Therapeutics Inc. - March 202316 -4 -3 -2 -1 0 -50 0 50 100 Log [bsAb] (nM) % S pe ci fic C yt ot ox ic ity Negative Control IMC-2-7 CTIM-76 IMC-2-7
Slide 17: Identification of Selective CLDN6 MAbs
Identification of Selective CLDN6 MAbs Discovery of CTIM-76 Context Therapeutics Inc. - March 202317 • IM301 (CLDN6 arm of CTIM-76) exhibits high CLDN6 selectivity1 • Epitope mapping of IM301 identifies unique binding location relative to benchmark IMAB027/ASP150 (Ganymed/Astellas) IMAB027/ASP1650 I
Slide 18: CTIM-76 Exhibits Excellent Selectivity
CTIM-76 Exhibits Excellent Selectivity Discovery of CTIM-76 Context Therapeutics Inc. - March 202318 • CTIM-76 CLDN6 EC50 of 3.41 nM • CTIM-76 preferentially binds to CLDN6 over CLDN3/4/9 • CLDN3/4/6/9 were transiently transfected in HEK-293F cells (4:1 Target:GFP) CLDN6 Selectivity -11 -10 -9 -8 -7
Slide 19: CTIM-76 Preferentially Targets CLDN6 Over Other Claudin Family Proteins
CTIM-76 Preferentially Targets CLDN6 Over Other Claudin Family Proteins Discovery of CTIM-76 Context Therapeutics Inc. - March 202319 • There is high sequence homology between CLDN6 and CLDN9 in the extracellular loops • CTIM-76 preferentially targets CLDN6, with minimal activity against CLDN9-expre
Slide 20: CTIM-76 Activity Requires CLDN6 Expression
CTIM-76 Activity Requires CLDN6 Expression T-cell mediated cell killing is dependent on CLDN6 expression Discovery of CTIM-76 Context Therapeutics Inc. - March 202320 K562-CLDN6 OV90 HEK CLDN6 Expression High Medium Low CTIM-76 (EC50) 0.0004 nM 0.049 nM 2.79 nM OV90 Cell LineK562-CLDN6 Cell Line HEK
Slide 21: CTIM-76 has the Potential for a Wide Therapeutic Window
Discovery of CTIM-76 Context Therapeutics Inc. - March 202321 CTIM-76 has the Potential for a Wide Therapeutic Window • Data supports potential to dose at levels that promote cancer cell killing but have manageable levels of free cytokine production, thereby potentially reducing the risk of cytokine
Slide 22: Competitive Landscape
Competitive Landscape 22 Context Therapeutics Inc. - March 2023
Slide 23: Mapping the T-cell Directed Therapy Landscape
Mapping the T-cell Directed Therapy Landscape1 Competitive Landscape Context Therapeutics Inc. - March 202323 Large Addressable Patient Population Small Addressable Patient Population Validated Target Emerging Target PRAME MAGE-A4 CLDN6 CLDN18.2 NY-ESO-1 MSLN gp100 CD19 COL6A3AFP ENPP3 B7-H3 CD20 FL
Slide 24: CLDN6 – Drug Development Strategy Comparison
CLDN6 – Drug Development Strategy Comparison CLDN6 is a tumor-associated antigen (TAA) for tumor-targeting therapeutics such as CAR-T and T cell engaging bispecific antibodies Competitive Landscape Context Therapeutics Inc. - March 202324 Drug Development Strategy CLDN6 Dependence / Rationale Suppor
Slide 25: CLDN6 Competitive Landscape
CLDN6 Competitive Landscape1 Programs differentiated based upon treatment modality and selectivity for CLDN6 over CLDN9 Competitive Landscape Context Therapeutics Inc. - March 202325 Preclinical Phase 1 Antibody Drug Conjugate (ADC) Bispecific Antibody Cell Therapy CLDN6-CAR-NK CAR-NK + IL7 (not dis
Slide 26: Potential for CTIM-76 to Separate From the Competition
Potential for CTIM-76 to Separate From the Competition Company Program (Development Stage) Description / Details3 Active Programs BioNTech BNT211: CLDN6CAR-T + CARVac (Phase 1) Initial data for BNT211 were presented April 2022 (AACR), with an update in Sept 2022 (ESMO). Received PRIME Designation fo
Slide 27: Corporate
Corporate 27 Context Therapeutics Inc. - March 2023
Slide 28: Experienced Leadership Team
Corporate Experienced Leadership Team • Experienced team with deep oncology experience • Our CMO led the clinical development of multiple blockbuster drugs including Kisqali, Arimidex, and Afinitor • Our management team is supported by a Board with strong public company operating and governance expe
Slide 29: Investment Highlights
Corporate Investment Highlights (Nasdaq: CNTX) Solid Tumors Large Unmet Need Claudin 6 High-Value Target Preclinical Update at AACR 2023 Near-Term Milestones Deep Domain Experience, Track Record of Success Strong Team Expected Cash Runway into late 2024 Financial Strength Context Therapeutics Inc. -
Slide 30: Advancing Medicines for Solid Tumors
Advancing Medicines for Solid Tumors © Context Therapeutics 2023
Context Therapeutics — Investor Presentation (March 2023) on 6ix